In close collaboration with experts at AstraZeneca, the Broad Institute’s Deverman laboratory developed Covid-19 CG in 2020 as an open resource for scientists responding to the pandemic. Over the past five years, the browser has been used by numerous groups internationally to monitor diagnostic target sites and develop diagnostics for new variants, analyze mutations that may impact therapeutic antibodies or small molecules, understand the breadth of mutations in a genomic region of interest, track the emergence and frequency of mutations over time and in different locations, and follow global sequencing efforts. We were gratified to hear that Covid-19 CG contributed to the development of therapeutics and diagnostics during the pandemic. We could not have created Covid-19 CG without the unparalleled GISAID EpiCoV resource as well as the generous sponsorship and the expertise shared by AstraZeneca UK and US. We are pausing active development of Covid-19 CG and will reassess future needs as the public health landscape evolves.

Link to our 2021 eLife paper: https://elifesciences.org/articles/63409.

Code for the project is hosted on GitHub: https://github.com/vector-engineering/covidcg.